FGF9 and prostate carcinoma: In patients with prostate cancer, high expression levels of CX3CR1 were required for FGF9 to activate FGFR1 signaling (Figure 9D), and CX3CR1 was positively associated with FGFR1 activation under FGF9 secretion (Figure 9G).